The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib (AACR-NCI-EORTC 2022) - Sep 3, 2022 - Abstract #97; PB087; Pres time: Oct 26, 2022; 12:00 PM - 08:00 PM; Location: Exhibition Hall; "ENV-201-mediated ULK1 inhibition thus shows promise as both a single agent or in combination with a growth factor/RAS/MAPK pathway-targeting cancer treatment."
Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS
|
|
J. Pitman1; L. Dellamary1; S. Kc1; M. de los Rios1; J. Hood1
|